Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsBertrand Routy, Laurence Zitvogel, Emmanuelle Le Chatelier et al.|Science|2017Cited by 5.4k
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelinesKetty Peris, Maria Concetta Fargnoli, Claus Garbe et al.|European Journal of Cancer|2019Cited by 589
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Guido Kroemer, Enrico Lugli et al.|Oncotarget|2014Cited by 469
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Jean‐Jacques Grob et al.|The Lancet Oncology|2021Cited by 389
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophageAurélie Fluckiger, Vincent Cattoir, Romain Daillère et al.|Science|2020Cited by 382